Comparative evaluation of flow-cytometric immunophenotyping and immunocytochemistry in the categorization of malignant small round cell tumors in fine-needle aspiration cytologic specimens.
 

Posts


Write a Post
12-17-08 08:10 AM
Anonymous
Comparative evaluation of flow-cytometric immunophenotyping and immunocytochemistry in the categorization of malignant small round cell tumors in fine-needle aspiration cytologic specimens.
Reply

Comparative evaluation of flow-cytometric immunophenotyping and immunocytochemistry in the categorization of malignant small round cell tumors in fine-needle aspiration cytologic specimens.

Cancer. 2008 Dec 15;

Authors: Gautam U, Srinivasan R, Rajwanshi A, Bansal D, Marwaha RK

BACKGROUND.: The precise diagnosis of malignant small round cell tumors (MSRCTs) in fine-needle aspiration (FNA) cytology is a challenge that requires ancillary investigations. In this study, the authors evaluated the applicability of flow-cytometric immunophenotyping (FCI) and compared it with immunocytochemistry (ICC) for the accurate categorization of MSRCTs. METHODS.: In total, 37 consecutive MSRCTs that had been diagnosed with FNA cytology were analyzed by ICC and FCI using a panel of antibodies against desmin, vimentin, CD99/major histocompatibility class I-related antigen 2, neuron-specific enolase, and pancytokeratin. The final diagnoses included Ewing sarcoma (n = 17), rhabdomyosarcoma (n = 6; 4 embryonal and 2 alveolar subtypes), neuroblastoma (n = 10), desmoplastic small round cell tumor (n = 2), and retinoblastoma (n = 2). RESULTS.: Accurate categorization was possible in 67.5% of cases by ICC and in 64.8% of cases by FCI. Concordant immunophenotyping results with either technique were obtained in 21 cases (59.4%). Low cellularity of the sample and negativity for all markers tested were some limitations to both techniques when applied on fine-needle aspirates. However, using a combination of both techniques, 86.4% (32 of 37 cases) MSRCTs were typed accurately. CONCLUSIONS.: FCI is applicable on FNA material and complements ICC in accurate the typing of MSRCTs. This is particularly useful in advanced-stage disease, when neoadjuvant chemotherapy may be instituted promptly. Cancer (Cancer Cytopathol) 2009. (c) 2008 American Cancer Society.

PMID: 19073016 [PubMed - as supplied by publisher]